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SUMMARY 
Tumor-derived extracellular vesicles (TEV) “educate” healthy cells to promote metastases. We found 
that melanoma TEV downregulated type I interferon (IFN) receptor and expression of IFN-inducible 
cholesterol 25-hydroxylase (CH25H). CH25H produces 25-hydroxycholesterol, which inhibited TEV 
uptake. Low CH25H levels in leukocytes from melanoma patients correlated with poor prognosis. Mice 
incapable of downregulating the IFN receptor and Ch25h were resistant to TEV uptake, TEV-induced pre-
metastatic niche and melanoma lung metastases; however, ablation of Ch25h reversed these 
phenotypes. An antihypertensive drug reserpine suppressed TEV uptake and disrupted TEV-induced 
formation of the pre-metastatic niche and melanoma lung metastases. These results suggest the 
importance of CH25H in defense against education of normal cells by TEV and argue for use of reserpine 
in adjuvant melanoma therapy.  
 
SIGNIFICANCE  
Education of normal cells by factors delivered via the tumor-derived vesicles promotes tumor 
growth, progression and metastasis. Results of this study uncover the key role of CH25H in defense 
against normal cells education by tumor-derived vesicles and, accordingly, against melanoma 
progression and metastatic disease. In addition, these data provide a proof-of-principle for interfering 
with tumor-derived extracellular vesicles uptake as a strategy for adjuvant treatment of metastatic 
melanoma and suggest the repurpose of reserpine for such application.  
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INTRODUCTION 
Whereas metastases are the most important determinants of cancer lethality (Chaffer and 
Weinberg, 2011), there is a relative dearth of clinically validated specific targets and agents that either 
eliminate the existing metastatic lesions, or, at the very least prevent initial metastases and suppress 
their colonization (Steeg, 2016). Normal cells in target organs can form a hospitable “soil” (Fuchs, 1882; 
Paget, 1889) enabling malignant cells to home and colonize. Given genomic instability and extreme 
plasticity of malignant cells, targeting these normal cells might represent a promising therapeutic 
strategy against metastatic disease.  
The metastatic process in many cancer types is stimulated by tumor-derived extracellular vesicles 
(TEV), including exosomes (Costa-Silva et al., 2015; Peinado et al., 2012). These vesicles can dramatically 
affect normal cells by delivering biomolecules that alter the function of these cells (Aleckovic and Kang, 
2015; Becker et al., 2016; Kalluri, 2016; Lobb et al., 2017; Peinado et al., 2012). Such “education” by TEV 
can co-opt normal cells to contribute to tumor progression and metastasis via multiple mechanisms 
including formation of the pre-metastatic niches in distant healthy organs such as the lungs (Liu et al., 
2016; Lobb et al., 2017).  
However, the majority of normal cells in a tumor-bearing organism exhibits limited uptake of TEV 
(Mendt et al., 2018) and appears to remain unaffected suggesting the existence of yet to be identified 
defensive mechanisms that restrict the extent of education by TEV. Here we sought to identify the 
nature of such defenses in normal cells as well as potential mechanisms underlying their breach and 
failure during tumor progression and metastasis. In addition, we aimed to identify and characterize the 
agents that can disrupt the education of normal cells by TEV and thus may have therapeutic activities in 
the adjuvant/neoadjuvant setting. 
RESULTS 
TEV inactivate the IFN pathway to facilitate TEV uptake and education of normal cells 
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TEV-driven education of normal cells is attributed to transfer of diverse biomolecules including 
signaling receptors (reviewed in (Aleckovic and Kang, 2015; Becker et al., 2016; Kalluri, 2016; Lobb et al., 
2017; Peinado et al., 2012)). We used a Stable Isotope Labeling by Amino Acids in Cell Culture (SILAC)-
based Plasma Membrane Profiling proteomic screen (Matheson et al., 2015; Weekes et al., 2013) (Figure 
S1a) to determine changes in the repertoire of cell surface signaling receptors in human cells exposed to 
TEV (characterized in Figure S1b). Comparative mass spectrometry revealed that TEV treatment 
decreased the levels of several plasma membrane proteins (Table S1) including the IFNAR1 chain of the 
type I interferon (IFN) receptor (Figure 1a). We further focused on IFNAR1 because of the important role 
of IFN in defense against tumor metastases (Parker et al., 2016) and clinical use of these cytokines in 
adjuvant therapy of melanoma (Eggermont et al., 2014). 
TEV derived from melanoma cells did not alter the levels of IFNAR1 mRNA (Figure S1c) but notably 
decreased IFNAR1 protein (Figure 1b and S1d) without inducing activation of STAT1 (Figure S1d) 
suggesting that TEV downregulate IFNAR1 in an IFN-independent manner. Previous reports 
demonstrated that non-ligand stimuli activate p38α protein kinase-dependent phosphorylation of 
IFNAR1 on Ser residues (Bhattacharya et al., 2011). This phosphorylation enables the βTrcp E3 ubiquitin 
ligase to facilitate IFNAR1 ubiquitination and degradation (Bhattacharya et al., 2013; Fuchs, 2013; 
Huangfu et al., 2012; Liu et al., 2009; Qian et al., 2011). Given that TEV encompass diverse types of RNA 
that can trigger a number of signaling cascades including p38 activation (Liu et al., 2016), we examined 
the impact of TEV on this pathway. TEV treatment had a modest effect on βTrcp but activated p38 
kinase (Figure S1d) and stimulated IFNAR1 Ser phosphorylation and ubiquitination (Figure 1c). 
Furthermore, a p38 inhibitor prevented IFNAR1 loss (Figure S1e) suggesting that TEV act as inducers of 
p38-dependent IFNAR1 downregulation. 
To determine the relevance of these observations to naturally occurring melanoma, we examined 
whether extracellular vesicles isolated from melanoma patients can downregulate IFNAR1 and whether 
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IFNAR1 is indeed downregulated in normal cells from melanoma patients. Plasma-derived vesicles from 
melanoma patients (but not from healthy donors) indeed decreased the levels of IFNAR1 protein but not 
mRNA in human cells in vitro (Figure 1d and S1f). Furthermore, lower levels of the cell surface IFNAR1 
protein (but not mRNA) were found in leukocytes from melanoma patients compared to those from 
healthy donors (Figure 1e and S1g). Importantly, the extent of IFNAR1 downregulation was greater in 
patients with documented metastatic lesions (Figure 1e). Given that an increase in TEV was associated 
with metastatic melanoma (Peinado et al., 2012), these data are consistent with downregulation of 
IFNAR1 on normal cells as a hallmark of their education by TEV in patients.  
Understanding of importance of IFNAR1 downregulation as a part of education of normal cells by 
TEV requires modeling the effects of TEV in vitro and in vivo. Extracellular vesicles isolated from cultured 
B16F10 mouse melanoma cells (but not from normal primary mouse lung fibroblasts) robustly induced 
p38 kinase activation and downregulated IFNAR1 in primary mouse splenocytes (Figure 1f). 
Furthermore, ablation of Mapk14 (gene that encodes p38α) in these splenocytes attenuated the loss of 
IFNAR1 upon exposure to TEV (Figure 1g) suggesting that normal mouse cells can recapitulate the p38-
driven loss of IFNAR1.  
In order to evaluate the importance of TEV-induced downregulation of IFNAR1, we used Ifnar1S526A 
knock-in mice, which are deficient in IFNAR1 ubiquitination and degradation (characterized in 
(Bhattacharya et al., 2014; Katlinski et al., 2017) and henceforth termed “SA”). SA splenocytes were 
resistant to TEV-induced downregulation of IFNAR1 in vitro (Figure 1g). Furthermore, intravenous 
injection of TEV in vivo downregulated IFNAR1 levels on the surface of wild-type (WT) (but not SA) 
leukocytes (Figure S1h). Finally, lower levels of IFNAR1 on peripheral blood leukocytes were detected in 
tumor-bearing WT (but not SA) mice compared to naive animals (Figure 1h) indicating that SA cells and 
animals can be used as controls for assessing the importance of IFNAR1 loss in TEV-induced education.  
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IFNAR1 is required for all effects of Type I IFN but not Type II IFNγ (Platanias, 2005). Accordingly, 
pre-treatment of mouse cells with TEV attenuated phosphorylation of STAT1 induced specifically by 
IFNβ but not by IFNγ (Figure 2a and S2a) suggesting that TEV can inactivate IFNAR1 signaling. Whereas 
extracellular vesicles from normal fibroblasts induced expression of some of IFN-stimulated genes (ISG) 
consistent with a previous report (Boelens et al., 2014), TEV notably suppressed this expression (Figure 
2b). An even greater suppression of ISG was elicited by multiple treatments imitating continuous 
education by TEV (Figure S2b). These observations in mouse cells were faithfully recapitulated in human 
cells where expression of ISG was inhibited by extracellular vesicles from melanoma patients (but not 
from healthy donors, Figure 2c) indicating that TEV can inactivate the IFN-IFNAR1 pathway.  
The ISG were not suppressed if cells were exposed to IFN before TEV (Figure S2c) indicating that IFN 
may cancel the effect of TEV. Importantly, control experiments revealed that pre-treatment of cells with 
IFN impeded TEV uptake in splenocytes (Figure 2d and S2d). These results may suggest that IFN and TEV 
can mutually counteract each other’s effects: whereas IFNAR1 will be inactivated in cells first exposed to 
TEV, signaling through active IFNAR1 should limit the education by TEV.  
Indeed, SA cells resistant to TEV-induced IFNAR1 downregulation (Figure 1g-h, S1h) also did not 
respond to TEV by decreasing IFN signaling (Figure 2a and S2a) or the ISG expression (Figure 2b). 
Importantly, SA cells were relatively refractory to TEV uptake in vitro compared to WT or Ifnar1-null cells 
(Figures 2d, e and S2d, e). TEV uptake in SA cells was restored by neutralizing antibody against IFNAR1 
(Figures 2e and S2e) demonstrating a critical role of IFNAR1 signaling in this phenotype. The SA mice 
were also resistant to in vivo uptake of TEV by splenocytes and bone marrow cells (Figure 2f and S2f). 
These results suggest the importance of IFNAR1 in limiting TEV uptake and TEV-elicited education of 
normal cells.  
TEV administration in vivo was shown to educate normal cells and induce the pre-metastatic niche 
in the lungs characterized by pulmonary myeloid infiltration and fibronectin deposition (Kaplan et al., 
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2005; Peinado et al., 2012). Intriguingly, treatment of WT (but not SA) mice with TEV led to a notable 
loss of IFNAR1 protein (Figure 3a) and decreased ISG mRNAs (Figure 3b) in lung tissues. These results 
suggest that education of normal cells by TEV in vivo includes inactivation of IFNAR1 signaling and 
further justifies using SA animals as a negative control in experiments assessing the importance of this 
education.  
Consistent with published results (Peinado et al., 2012) we found that administration of TEV 
promoted formation of the CD11b+ myeloid clusters (Figure 3c and S3a), and fibronectin deposits (Figure 
3d and S3b) in the lungs of WT mice. Importantly, lung tissues from TEV-treated SA mice exhibited fewer 
CD11b+ cell clusters or fibronectin deposits and lower overall lung myeloid infiltration compared to WT 
mice (Figures 3c-d and S3b-c). Given that poor myeloid infiltration in SA lungs was reversed by 
administration of the neutralizing antibody against IFNAR1 (Figure S3d), these data suggest that 
formation of the TEV-induced pre-metastatic niche requires inactivation of IFNAR1 and ensuing 
disruption of the IFNAR1-mediated defenses against education of normal cells by TEV. 
Lyden and co-authors demonstrated a notable stimulation of primary tumor growth and metastases 
in irradiated host mice that received transfer of the educated bone marrow from TEV-treated donor 
mice (Peinado et al., 2012) (Figure 3e). Consistent with this report, we found that transplantation of 
bone marrow from TEV-treated WT mice indeed stimulated lung metastases in WT recipients inoculated 
with B16F10 tumors (Figures 3f). Importantly, we did not observe such stimulation when bone marrow 
was taken from TEV-treated SA mice (Figure 3f). These results suggest that IFNAR1 in normal cells is 
important to interrupt their education by TEV and, consequently, to provide defense against TEV-
stimulated metastases.  
IFN-induced CH25H limits uptake of TEV and interrupts the education of normal cells 
We next sought to determine how IFNAR1 signaling can suppress TEV uptake and disrupt TEV-
induced education of normal cells. Uptake of extracellular vesicles can occur through a number of 
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mechanisms including phagocytosis, endocytosis, micropinocytosis, direct membrane fusion, etc (French 
et al., 2017). Bone marrow macrophages from SA mice were not deficient in phagocytosis compared to 
WT macrophages (Figure S4a). Fortuitously, we also observed that IFN suppressed the uptake of empty 
protein-less liposomes (Figure S4b) suggesting an inhibitory effect of IFN on lipid membrane fusion, 
which is involved in many types of TEV uptake (French et al., 2017). 
Indeed effects of IFN on lipid membrane fluidity have been previously reported (Chatterjee et al., 
1982). Recent findings suggest that cholesterol 25-hydroxylase (CH25H), an enzyme generating 25-
hydroxycholesterol (25HC) that alters membrane characteristics (Luu and Moog, 1991) can be induced 
by IFN (Anggakusuma et al., 2015; Blanc et al., 2013; Liu et al., 2013). Pre-treatment of cells with 25HC 
suppressed uptake of liposomes in WT cells as well as in cells lacking Ifnar1 or Ch25h (Figure S4b) 
suggesting that this oxysterol acts downstream of these genes. Cells exposed to 25HC also exhibited a 
decreased uptake of TEV (Figure 4a and S4c). Importantly, IFN did not inhibit uptake of liposomes or TEV 
in cells lacking Ch25h (Figure 4a and S4b-c). Furthermore, ablation of Ch25h in SA mice restored the 
ability of tissues from these animals to uptake TEV in vivo (Figures 4b and S4d) suggesting that Ch25h 
acts downstream of IFNAR1 to restrict the education of normal cells by TEV.  
Of note, TEV downregulated Ch25h expression whereas vesicles from primary fibroblasts did not 
(Figure S4e). Opposite effects on Ch25h were elicited by IFN and TEV, but these stimuli did not affect 
other monooxygenases involved in cholesterol oxidation such as Cyp46a and Cyp27a (Figure S4e). 
Tissues from naive SA mice expressed higher levels of Ch25h compared to those from WT mice (Figure 
S4f). Furthermore, WT cells exposed to TEV in vitro exhibited lower levels of Ch25h compared to those 
from SA mice (Figure 4c). Importantly, administration of TEV in vivo decreased Ch25h in lung tissues 
from WT but not SA mice (Figure 4d) indicating the importance of IFNAR1 loss for downregulation of 
Ch25h. Remarkably, ablation of Ch25h in SA mice restored TEV-induced formation of pre-metastatic 
niche as seen from accumulation of CD11b+ clusters and fibronectin deposits in the lungs (Figure 4e). 
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This result indicates a defensive role of the IFNAR1-CH25H pathway against TEV-induced education of 
normal cells and the ensuing development of a pre-metastatic niche.  
Suboptimal bioavailability of 25HC (Li et al., 2017) prompted us to search for small molecules that 
can mimic the suppressive effects of this oxysterol on TEV uptake. A limited hypothesis-driven screen 
tested the agents previously reported to inhibit biological processes that involve lipid membrane fusion 
such as viral membrane fusion (Boriskin et al., 2006; Shoemaker et al., 2013) , neuromediator re-uptake 
(Erickson et al., 1992), maturation of myocytes and osteoclasts (Bar-Sagi and Prives, 1983; Okazaki et al., 
1999; Yamashita et al., 2010), etc (Table S2). Among six tested compounds, the anti-hypertensive drug 
reserpine was found to interfere with B16F10 TEV uptake by mouse splenocytes or bone marrow cells 
(Figure S5a). These results were further validated in vitro in human cells (Figure 5a and S5b).  
Furthermore, administration of reserpine in vivo also suppressed TEV uptake (Figure 5b and S5c), 
prevented TEV-induced downregulation of IFNAR1 (Figure 5c) and stimulated ISG including Ch25h 
(Figure S5d) in normal cells. Importantly, treatment with reserpine abolished TEV-induced formation of 
the pre-metastatic niche as evident from analysis of lung myeloid infiltrates and fibronectin deposits 
(Figure 5d and S5e). These results suggest that reserpine can be used to disrupt TEV-induced education 
of normal cells and the generation of the pre-metastatic niche. 
Anti-metastatic role of the IFNAR1-CH25H pathway and potential for adjuvant therapy utilizing 
inhibitors of TEV uptake 
Given that the IFNAR1-dependent expression of Ch25h limits the education of normal cells by TEV, 
which, in turn, can stimulate tumor metastases (Chin and Wang, 2016a; Chin and Wang, 2016b; Costa-
Silva et al., 2015; Peinado et al., 2012; Peinado et al., 2011), we sought to examine the putative anti-
metastatic role of this pathway. First, we evaluated its status in human melanoma. Extracellular vesicles 
isolated from melanoma patients (but not healthy donors) decreased CH25H expression in human cells 
in vitro (Figure 6a). In addition, leukocytes from melanoma patients with metastatic disease expressed 
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less CH25H than healthy donors or melanoma patients without metastases (Figure 6b). Furthermore, 
melanoma patients expressing lower CH25H than the average level in healthy donors had increased 
occurrence of distant metastases (Figure 6c) and displayed a poor survival (Figure 6d). These results 
suggest that downregulation of CH25H in normal cells may breach the CH25H-mediated defenses 
against melanoma progression and metastases. 
To further examine this possibility we used a syngeneic metastatic tumor model in mice harboring 
WT or SA IFNAR1. In these experiments, we did not administer additional TEV but rather relied on TEV 
production by subcutaneous B16F10 tumors, which were shown to generate abundant endogenous TEV 
(Liu et al., 2016; Peinado et al., 2012). Many more of disseminated B16F10-TdTomato cells were found 
in the lungs of WT mice compared to SA animals (Figure S6a-b) indicating the importance of IFNAR1 
inactivation for efficient metastatic process. 
A delayed growth of primary B16F10 tumors observed in SA mice (Figure S6c) was similar to other 
tumor models (Katlinskaya et al., 2016; Katlinski et al., 2017). This delay was partially alleviated by 
knockout of Ch25h in SA mice. Resection of tumors growing in SA mice was postponed until they 
reached a volume ~200 mm2 similar to that in other genotypes (Figure S6c). At that point, we excised 
primary tumors and examined post-surgical survival and appearance of lung metastases. Under these 
conditions, WT and Ch25h-/- mice developed massive lung metastatic disease (Figure 6e-f) that led to 
100% lethality within a month (Figure 6g). When primary tumors of similar size were resected from SA 
mice, they displayed virtually no detectable lung metastases and a dramatic improvement in post-
surgical survival (Figure 6e-f-g). These data further support the importance of IFNAR1 signaling in normal 
cells in protection against metastatic disease.  
Remarkably, the ablation of Ch25h in SA mice completely reversed the suppression of lung 
metastases (Figure 6e-f) and abolished the extended survival (Figure 6g). This result suggest that CH25H 
acts epistatically downstream of IFNAR1 to elicit the defenses against tumor metastasis in normal cells. 
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Given that the IFNAR1-CH25H pathway also protects these normal cells against TEV uptake (Figure 4b) 
and pre-metastatic niche-stimulating education by TEV (Figure 4e), it is plausible that preventing 
education by TEV may restore the defenses against metastases, for example, in the context of adjuvant 
or neoadjuvant therapies. 
Thus, we examined the anti-metastatic activities of reserpine that can inhibit TEV uptake (Figure 5a-
b), remediate the loss of IFNAR1 and Ch25h (Figures 5c and S5d) and disrupt formation of TEV-induced 
pre-metastatic niche (Figure 5d). Reserpine treatment of B16F10 cells in vitro did not dramatically affect 
their proliferation (Figure S7a) or characteristics of produced TEV (Figure S7b) or ability of these TEV to 
induce the myeloid infiltration in the lungs in vivo (Figure S7c).  
We next assessed the effects of reserpine in the B16F10 tumor-bearing mice. Early studies reported 
that administration of reserpine inhibited tumor growth but attributed this effect to a severely 
tranquilized state and dramatic loss of weight due to a failure of sleeping animals to eat or drink for 
protracted periods of time (Belkin and Hardy, 1957; Burton et al., 1957). Here we used moderate 
reserpine doses, which were well tolerated and did not decrease animal weight throughout the 
experiments (Figure S7d). Importantly, reserpine treatment restored IFNAR1 levels in peripheral blood 
leukocytes (Figure 7a) and upregulated Ch25h and other ISGs in the lungs of tumor-bearing animals 
(Figure S7e) suggesting a successful disruption of education of normal cells by endogenously produced 
TEV. 
When administered alone, reserpine had rather modest effects on primary tumor growth (Figure 
S7f) and cancer-related survival (Figure 7b) indicating its limited utility as a single agent. We next 
examined the efficacy of reserpine in the context of adjuvant/neo-adjuvant therapy (Figure 7c). Primary 
tumors were grown to ~200 mm2 (Figure S7g) followed by their surgical removal and reserpine was 
administered before and after surgery (Figure 7c).  Although recurrence of primary tumors and tumors 
growing in the lymph nodes (that were not removed during the surgery) forced the euthanasia of some 
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of animals, the overall survival was significantly improved by reserpine (Figure 7d). Subsequent analysis 
showed that reserpine virtually eliminated lung metastases (Figure 7e-f) indicating a great potency of 
reserpine as an adjuvant therapeutic agent.   
DISCUSSION 
Data presented here suggest that IFNAR1-mediated expression of CH25H in healthy tissues limits 
the extent of education of these tissues by TEV and, accordingly, restricts the overall area of the pre-
metastatic niche in the lungs. Accordingly, these results suggest a defensive role of the IFNAR1-CH25H 
pathway against development of distant lung metastases. Whereas limited analysis of leukocytes from 
melanoma patients is suggestive of association between the loss of CH25H and poor disease outcome, 
future extensive studies should determine the value of CH25H expression as potential prognostic 
biomarker in patients with melanoma and other highly metastatic cancers.  
Among other signaling pathways, activation of p38 kinase was observed during the education of 
normal lung cells by TEV that encompass RNA and other damage-associated molecular patterns (Liu et 
al., 2016). Whereas activation of p38 is important for TEV-driven loss of IFNAR1, additional studies 
should characterize the nature of these diverse (and likely redundant) TEV-carried substances that elicit 
IFNAR1 inactivation. Given that CH25H is an IFN-inducible gene (Anggakusuma et al., 2015; Liu et al., 
2013) and knockout of this gene abolishes the suppression of metastases in mice that maintain the 
expression of downregulation-resistant IFNAR1 mutant, it is likely that CH25H functions downstream of 
IFNAR1.  
Accordingly, continuous exposure to TEV and TEV-induced loss of IFNAR1 may contribute to 
suppression of this defensive pathway in normal cells. Despite re-synthesis of IFNAR1, its rapid 
ubiquitination and degradation in cells, which encounter TEV before IFN, would further stimulate uptake 
of TEV and, thereby, perpetuate the positive feedback loop of IFNAR1/CH25H inactivation. In turn, this 
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positive feedback would ensure continuous education of normal cells leading to generation of the 
metastatic niches and promoting cancer metastasis.  
Conversely, enabling normal cells to restore IFNAR1 and respond to IFN by induction of CH25H is 
expected to interrupt the education by TEV. Indeed, IFN counteracts the effects of TEV on normal cells 
through maintaining CH25H expression and limiting TEV uptake. It remains to be determined, which of 
many types of TEV uptake (e.g. endocytosis, macropinocytosis, direct fusion, etc) are regulated by 
CH25H. Although CH25H product 25HC can act as a ligand for activating the nuclear Liver X Receptor 
(that can play anti-tumorigenic roles) a number of oxysterol-elicited effects were shown to be 
independent of the Liver X Receptor (reviewed in (Traversari et al., 2014)). Importantly, another ligand 
of this receptor, 27-hydroxycholesterol, was recently shown to promote the metastatic process through 
acting on immune cells (Baek et al., 2017). Notably, IFN did not induce the expression of Cyp27a, which 
catalyzes production of 27-hydroxycholesterol. Regardless of these considerations and, given that anti-
tumorigenic agonists of the Liver X Receptor are being developed (Flaveny et al., 2015), future studies 
should determine its role in 25HC-dependent protection of normal cells against TEV education.  
Furthermore, 25HC and reserpine may possess additional anti-tumorigenic activities unrelated to 
their ability to restrict TEV uptake. Although we did not observe that reserpine affects TEV production or 
ability of these TEV to educate normal cells, additional mechanisms of action for reserpine cannot be 
entirely ruled out. Independent of these considerations, our data suggest that reserpine (and perhaps 
other agents capable of disrupting TEV-induced education) can elicit potent adjuvant therapeutic 
activities.  
Limited benefits of IFN in patients who already have developed distant metastases restricts 
application of IFN to the sphere of adjuvant/neoadjuvant therapy (Eggermont et al., 2014; Tarhini et al., 
2012) aimed to disrupt the pre-metastatic niche and limit metastatic colonization. Our findings that 
protection of normal cells can be compromised by TEV-induced IFNAR1/CH25H downregulation argues 
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for shifting the strategy towards IFNAR1- and CH25H-independent modalities such as a low-dose 
reserpine regimen. Given that metastasis is a progressive process involving continuous education of 
normal cells, reserpine might be relevant not only for preventing this process but also for restricting the 
ongoing metastatic expansion. Being approved by the FDA since 1955 and deemed tolerable for patients 
with conditions far less grave than metastatic cancer, the clinical efficacy of reserpine in the context of 
adjuvant melanoma therapy should be tested posthaste.  
SUPPLEMENTAL INFORMATION  
Supplemental Information includes Supplemental Experimental Procedures, seven figures, and two 
tables and can be found with this article online. 
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Figure Legends 
Figure 1: TEV downregulate IFNAR1 in normal cells 
A. Volcano plot summarizing SILAC-based plasma membrane profiling results from THP-1 cells treated 
with 1205Lu human melanoma TEV. Mean log2(fold change) and -log10(p value) are shown for 366 
proteins identified by >1 unique peptide and quantitated in every replicate. Downregulated proteins 
with a fold change >2 and p<0.05 are outlined in red. 
B. Representative histogram of IFNAR1 cell surface levels measured by flow cytometry on THP-1 cells 
treated with 1205Lu human melanoma TEV (10 μg/106 cells for 2 hr) or PBS 
C. Effects of TEV (10 μg/106 cells for 30 min) on IFNAR1 phosphorylation and ubiquitination in THP-1 
cells. Immunoblot (IB) analyses of immunoprecipitated (IP) IFNAR1 using indicated antibodies are 
shown. Immunoblot analysis of βTRCP and GADPH levels in the whole cell lysate are also shown. 
D. Flow cytometry analysis of IFNAR1 cell surface levels on THP-1 cells treated with extracellular 
vesicles (5 μg for 2 hr) isolated from plasma of healthy donors (HDEV, n=8) or melanoma patients 
(MPEV, n=13) or PBS (n=7). A representative histogram (top) and quantification (bottom) are shown.  
E. IFNAR1 cell surface levels on peripheral blood leukocytes from healthy donors (HD; n=10) or 
melanoma patients (MP) from two independent cohorts: MP1 (40 patients of stages I-IV) and MP2 
20 patients in each of two groups that were positive (SLN+) or negative (SLN-) for sentinel lymph 
node metastases. A representative histogram (top) and ΔMFI quantification (bottom) are shown. 
F. Effect of extracellular vesicles from B16F10 (TEV, 10 µg/106 cells, 2 hr) or from primary mouse lung 
fibroblasts (FEV, 20 µg/106 cells, 2 hr) on IFNAR1 surface level (analyzed by flow cytometry, top) or 
p38 activation (analyzed by immunoblotting, bottom) in primary mouse splenocytes. 
G. Effect of B16F10 TEV treatment (10 µg/106 cells for 2 hr) on IFNAR1 surface level on splenocytes of 
indicated genotypes. 
H. Analysis of IFNAR1 cell surface levels on peripheral blood leukocytes from WT and SA mice (naive or 
bearing B16F10 tumors of equal size ~200 mm2, each n=4)  
 
Data are represented as mean ± SEM; p values: * p<0.05; ** p<0.01; *** p<0.001; NS, not significant 
from unpaired Student’s t test (panels A, D, E, H). 
See also Figure S1 and Table S1 
 
Figure 2: TEV and IFN counteract effects of each other 
A. Effect of pre-treatment with B16F10 TEV (10 µg/106 cells for 90 min) on activation of STAT1 by IFNβ 
(250 IU/mL for 30 min) or IFNγ (50 IU/mL for 30 min) in indicated mouse splenocytes analyzed by 
immunoblotting. 
B. qPCR analysis of mRNA for indicated genes in indicated mouse splenocytes treated with PBS, or 
extracellular vesicles from primary lung fibroblasts (FEV, n=3), or B16F10 (TEV, n=8) at 10 μg for 4 hr. 
C. qPCR analysis of mRNA for indicated genes in THP-1 cells treated with PBS (n=7) or with vesicles (5 
μg for 4 hr) from healthy donors (HDEV) (n=8) or melanoma patients (MPEV). (n=13) 
D. Uptake of DiD-labeled B16F10 TEV (10 µg for 4 hr) by WT or SA splenocytes pre-treated with PBS or 
mouse IFNβ (1000 IU/mL for 8 hr); n=6 for each group. 
E. Uptake of DiD-labeled B16F10 TEV (10 µg for 4 hr) by indicated splenocytes (106/mL) pre-treated 
with IgG control or anti-IFNAR1 (0.33 µg/mL for 1 hr); n=6 for each group. 
F. In vivo uptake of i.v. administered DiD-labeled B16F10 TEV (30 μg for 24 hr) by splenocytes and 
bone marrow cells of indicated mice; n=6 for each group. 
 
Data are represented as mean ± SEM; p values: * p<0.05; ** p<0.01; *** p<0.001; NS, not significant 
from Student’s t test. 
See also Figure S2 
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Figure 3: Inactivation of IFNAR1 promotes education of normal cells by TEV and generation of the 
pre-metastatic niche 
A. Immunofluorescence and quantification of IFNAR1 levels in lung tissues collected from indicated 
mice treated with indicated TEV (8 μg, 3x per week, 3 weeks). Red, IFNAR1; Blue, DAPI; Scale bar, 
100 μm; Quantification representing averages from 10 random fields in sections from each of 3 
different animals is shown in the right panel 
B. qPCR analysis of mRNA for indicated genes from lung tissues from panel A 
C. Immunofluorescence analysis of CD11b+ (green) clusters (>2 cells) in the lungs of WT and SA animals 
treated with PBS or B16F10 TEV (i.v., 8 µg 3x per week, 3 weeks). Scale bar - 100 µm; quantification 
representing averages from 7 random fields in sections from each of 3 different animals is shown in 
the bottom panel 
D. Immunofluorescence analysis of fibronectin (green) deposits in the lungs of WT and SA animals 
treated with PBS or B16F10 TEV (i.v., 8 µg 3x per week, 3 weeks). Scale bar, 100 µm; quantification 
representing averages from 7 random fields in sections from each of 3 different animals is shown in 
the bottom panel. 
E. Schematic of the experiments to evaluate the education of WT and SA bone marrow-derived cells by 
TEV and effect of this education on B16F10 tumor growth and metastasis 
F. Analysis and quantification of lungs from the td-Tomato-B16F10 tumors-bearing WT hosts that 
received GFP+ bone marrow derived cells (BMDCs) from WT or SA mice educated or not by TEV. 
Scale bar, 100 µm. Quantification represents averages from 7 random fields in sections from each of 
four different animals is shown in the right panel. 
 
Data are represented as mean ± SEM; p values: * p<0.05; *** p<0.001; NS, not significant from Student’s 
t test. 
See also Figure S3 
 
Figure 4: CH25H functions downstream of IFNAR1 to limit education of normal cells by TEV 
A. Uptake of DiD-labeled B16F10 TEV (10 µg for 4 hr) by splenocytes from indicated mice pre-treated 
with IFNβ (1000 IU/mL for 8 hr) or 25HC (4 µM for 2 hr) or vehicles as indicated; n=6 for each group.  
B. Analysis of DiD+ splenocytes and bone marrow cells isolated from mice of indicated genotypes 24 hr 
after i.v. administration of DiD-labeled B16F10 (30 μg); n=6 for each group. 
C. qPCR analysis of relative Ch25h mRNA levels in B16-F10 TEV-treated (10 µg, 4 hr) splenocytes or 
bone marrow cells of indicated genotypes (value of 1.0 ascribed to untreated WT cells) ; n=4 for 
each group. 
D. qPCR analysis of relative mRNA levels of Ch25h and other genes encoding cholesterol 
monooxygenases (Cyp27a and Cyp46a) in the lungs of WT or SA mice administered with PBS or 
B16F10 TEV (i.v., 8 µg, 3x per week, 3 weeks); n=4 for each group. 
E. Analysis of CD11b+ cell clusters and fibronectin deposits in the lungs of indicated mice treated with 
B16-F10 TEV (i.v., 8 µg, 3x per week, 3 weeks). Quantifications averaging from 7 random fields in 
sections from each of three different animals are shown. Scale bar, 100 µm. 
 
Data are represented as mean ± SEM; p values: * p<0.05; ** p<0.01; *** p<0.001; NS, not significant 
from Student’s t test. 
See also Figure S4 
 
Figure 5: Reserpine suppresses education of normal cells by TEV 
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A. Uptake of DiD-labeled 1205Lu TEV (10 µg for 4 hr) by THP-1 cells pre-treated with vehicle or 
reserpine (10 µM for 2 hr); n=3 for each group. 
B. Uptake of DiD-labeled B16F10 TEV (30 μg) by splenocytes and bone marrow cells isolated from WT 
mice 24 hr after i.p. injection of vehicle or reserpine (1 µg/kg i.p., given 30 min before TEV injection) 
followed by i.v. administration of TEV; n=6 for each group. 
C. Flow cytometry analysis of IFNAR1 levels on CD45+ peripheral blood leukocytes isolated from WT 
mice administered i.v. treatment with PBS or B16F10 TEV (8 μg, 3x per week, 3 weeks) and receiving 
i.p. vehicle or reserpine treatment (as in panel B) as indicated; n=3 for each group.  
D. Immunofluorescence analysis of CD11b+ cell clusters and fibronectin deposits in the lungs of WT 
mice receiving i.p. vehicle or reserpine treatment (as in panel B) followed by i.v. treatment with 
B16F10 TEV (8 μg, 3x per week, 3 weeks). 
 
Data are represented as mean ± SEM; p values: * p<0.05; ** p<0.01; *** p<0.001; NS – not significant 
from Student’s t test. 
See also Figure S5 and Table S2 
 
Figure 6: The IFNAR1-CH25H pathway protects against melanoma progression and metastasis 
A. qPCR analysis of CH25H mRNA levels in THP-1 cells treated with extracellular vesicles from healthy 
donors (HDEV, n=8)or melanoma patients (MPEV, n=13). 
B. qPCR analysis of CH25H mRNA levels in blood leukocytes from healthy donors (HD, n=10) or 
melanoma patients with (MET, n=17) or without (Non-MET, n=20) documented metastatic disease. 
C. Documented distant metastases in MP whose lymphocytes expressed greater (CH25Hhigh) or lower 
(CH25Hlow) levels of CH25H mRNA compared to healthy donors (HD); Fisher’s exact test: p value = 
0.000661 
D. Kaplan-Meier analysis of survival of melanoma patients classified as CH25Hhigh or CH25Hlow 
E. Representative H&E staining of lungs from indicated mice harvested 30 days after resection of s.c. 
B16F10 tumors of ~200 mm2. Examples of metastatic lesions are pointed by arrowheads.  
F. Quantification of total area of metastatic load in lungs from mice of indicated genotypes from panel 
E 
G. Kaplan-Meier analysis of cancer-related survival of indicated mice that underwent resection of 
B16F10 tumors as described in panel E.  
 
Data are represented as mean ± SEM; p values: * p<0.05; ** p<0.01; *** p<0.001; NS, not significant 
from Student’s t test (panels A, B, F), Fisher test (panel C) or log-rank test (panels D, G). 
See also Figure S6 
 
Figure 7: Activity of reserpine in the context of adjuvant/neoadjuvant therapy 
A. Flow cytometry analysis of IFNAR1 cell surface levels on peripheral blood leukocytes from naive WT 
mice (n=4) or WT mice bearing similar sized B16F10 tumors treated with vehicle or reserpine (i.p. 1 
mg/kg, 3x per week for 1 week; n=6 each). 
B. Kaplan-Meier survival analysis of B16F10 tumor bearing mice treated with vehicle or reserpine (i.p. 1 
mg/kg every 48 hr for 1 week) 
C. Schematic description of experiments assessing activity of reserpine as neoadjuvant/adjuvant 
therapeutic agent  
D. Kaplan-Meier analysis of cancer-related survival of mice described in panel C. 
E. Quantification of total area of metastatic load in lungs from mice described in panel C (Vehicle n=12, 
Reserpine n=16). 
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F. H&E staining of lungs from mice treated with vehicle or reserpine as in panel C and harvested 30 
days after surgery. Examples of metastatic lesions are pointed by arrowheads.   
 
Data are represented as mean ± SEM; p values: * p<0.05; ** p<0.01; *** p<0.001 from Student’s t test 
(panels A, E) or log-rank test (panels B, D). 
See also Figure S7 
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STAR METHODS 
Contact for Reagent and Resource Sharing 
Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead 
Contact, Serge Y. Fuchs (syfuchs@vet.upenn.edu) 
EXPERIMENTAL MODEL and SUBJECT DETAILS 
Animal Studies  
All experiments with animals were carried out under the protocol 803995 approved by the Institutional Animal Care 
and Use Committee (IACUC) of The University of Pennsylvania. All mice were of C57Bl/6 background and had 
water and chow ad libitum. Mice were maintained in a specific pathogen-free facility in accordance with American 
Association for Laboratory Animal Science guidelines. Littermate animals from different cages were randomly 
assigned into the experimental groups. These randomized experimental cohorts were either co-housed or 
systematically exposed to other groups’ bedding to ensure equal exposure to all group’s microbiota. Ch25h-/- and 
Ifnar1-/- mice were obtained from the Jackson Laboratory. Littermate Ifnar1+/+ (“WT”) and Ifnar1S526A mice (“SA”) 
were described previously (Bhattacharya et al., 2014). Other strains were generated by intercrossing and the 
littermates of 6-8 weeks of age were used in the experiments.  
Cell Culture 
Human and mouse cell lines such as human monocytic leukemia THP-1 cells (ATCC®TIB-202™), human 1205Lu 
melanoma (ATCC® CRL-2812™), and mouse B16F10 melanoma (ATCC® CRL-6475™) were purchased from 
ATCC and cultured according to the ATCC recommendations. Mouse mammary adenocarcinoma EO7771 cell line 
was purchased from CH3 Biosystems and cultured according to this provider’s recommendations.  
Human Samples 
Informed consent was obtained from all study participants. Study approval was given by the Institutional Review 
Board of the University of Pittsburgh. Use of previously collected lymphocyte samples that could not be directly or 
indirectly linked to individual human subjects was conducted under the strict guidance of the institutional review at 
the University of Pittsburgh Medical Center. 
 
METHOD DETAILS 
Analysis of human samples. The cell surface IFNAR1 levels on lymphocytes from healthy donors or patients from 
two independent cohorts of melanoma patients were analyzed by flow cytometry. The MP1 cohort consisted of 40 
patients with melanoma (stage I, II, III or IV). The MP2 cohort was described in details elsewhere (Tarhini et al., 
2017)). These patients had a sentinel lymph node involved (SLN+, n=20) or not (SLN-, n=20) by melanoma 
metastasis as assessed by H&E and immunohistochemistry. Combined samples from patients from both cohorts 
(minus two patient samples lacking sufficient amount of material to extract RNA) were analyzed for CH25H. 
Peripheral blood was aseptically collected into (green top) Na Heparin vacutainer tubes from healthy donors and 
melanoma patients. The blood was then stored at room temperature (16-30C) and processed as follows. Whole 
blood was diluted (1:2) in PBS and gently mixed before adding 10 mL of Lymphocyte Separation media. The 
sample was centrifuged for 5 min at 1000 rpm and without stopping the speed was increased to 1800-2000 rpm for 
20 min with the brake off. The peripheral blood leukocyte layer between the clear lymphocyte separation media and 
upper PBS layer was gently pipetted off. 
The cells were washed with PBS three times and suspended in media (Iscov’s Modified Dulbecco’s Medium, 10% 
Human Serum, 1% Pen-Strep solution, 1% L-Glutamine, 1% MEM non-essential amino acids 10mM, 1% HEPES 
Buffer solution 1M) with 10% DMSO for incubation at -80°C overnight before long term storage at -140°C. For 
recovery, frozen cells were thawed rapidly (< 1 minute) in a 37°C water bath by gently swishing the tube in the 
water without submerging. The thawed cells were slowly, but immediately, transferred into 10 ml of PBS. The cells 
were twice washed with PBS before flow cytometry analyses or RNA extraction. 
Blood samples were collected from patients with melanoma (n = 13) or healthy volunteers (n = 8) to isolate 
extracellular vesicles from plasma. Blood specimens were immediately processed by centrifugation at 1,000 x g for 
10 min at room temperature and plasma was separated and frozen in aliquots at -80°C. Frozen plasma samples were 
thawed and centrifuged at 2,000 x g for 10 min at room temperature and at 14,000 x g for 30 min at 4°C for 
thrombocyte removal. Centrifuged plasma was applied to a 0.22 µm-pore Millipore filter. Extracellular vesicle 
isolation was performed on mini-size exclusion chromatography columns as previously described (Hong et al., 
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2016). Briefly, plastic columns (Bio-Rad Econo-Pac columns, 1.5 cm x 12 cm) were packed with 10ml Sepharose 
2B including a frit on top (Sigma-Aldrich, St. Louis, MO, USA) and washed with phosphate buffered saline (PBS). 
Clarified plasma (1mL) was loaded on top of the column and then eluted with 1mL PBS per fraction. Fraction 4 was 
used for further investigations. Detailed characterization of these extracellular vesicles is described elsewhere 
(Sharma et al., 2018). 
Extracellular vesicles isolation from cell culture and labeling. The media from 80% confluent cells grown in 
Extracellular Vesicle-free (EV-free) was collected. The cancer cell extracellular vesicles were separated via 
ultracentrifugation as previously described (Thery et al., 2006).  Extracellular vesicles were characterized in size and 
number by the Characterization Core Facility in the University of North Carolina at Chapel Hill while corresponding 
images were taken by Analytical and Nanofabrication Laboratory in the University of North Carolina at Chapel Hill 
using TEM JEOL 100CX II scope.  Protein concentration was assessed using the Pierce BCA Protein Assay Kit.  
Extracellular vesicles were stored at -80°C for long term storage and thawed on ice before use. For labelling, 
extracellular vesicles were suspended in sterile PBS solution containing 5 µg/mL of the lipophilic dye DiD (Biotium 
Cat# 60014) dissolved in DMSO, incubated at 37°C for 10 min, transferred into ultracentrifugation tubes and washed 
twice with 35 mL of sterile PBS and re-suspended in PBS. 
Plasma Membrane Profiling Proteomic Screen. Plasma Membrane Profiling uses selective aminooxy-biotinylation 
and quantitative proteomics to compare the expression of cell surface receptors in experimental and control cells, and 
was performed as previously described (Matheson et al., 2015; Weekes et al., 2012; Weekes et al., 2013; Weekes et 
al., 2014). Briefly, for Stable Isotope Labelling with Amino Acids in Cell Culture (SILAC)-based quantitation, THP-
1 cells were pre-labeled for 7 days with light, medium or heavy isotopes of lysine and arginine (Cambridge Isotope 
Laboratories). Cells were then treated with either PBS or 1205Lu TEV (50 µg per 2x107 cells for 2 hr), washed in ice-
cold PBS and mixed in a 1:1 ratio. For aminooxy-biotinylation of plasma membrane proteins, cells were resuspended 
in a “one pot” aminooxy-biotinylation mix comprising 1mM sodium meta-periodate (Thermo Scientific), 100 µM 
aminooxy-biotin (Biotium) and 10mM aniline (Sigma) in ice-cold PBS pH 6.7 and incubated for 30 min in the dark. 
After lysis in 1% Triton X-100 (Thermo Scientific), biotinylated proteins were captured on High Capacity Streptavidin 
Agarose Resin (Thermo Scientific), stringently washed, reduced and alkylated prior to on-bead digestion with trypsin 
(Promega). Eluted peptides were subjected to LC–MS/MS using an RSLCnano 3000 (Thermo Scientific) coupled to 
a Q Exactive (Thermo Scientific). MS data were acquired from m/z 400 to 1650 with MS/MS spectra acquired in a 
top 10 DDA fashion. Raw MS files were processed using MaxQuant 1.5.0.0 and searched against a UniProt Homo 
sapiens database (downloaded 03/03/2014). Oxidation (M), deamidation (N/Q) and acetylation (Protein N-terminus) 
were set as variable modifications and carbamidomethyl (C) as a fixed modification. Peptide re-quantify was enabled 
and quantitation utilized razor and unique peptides. Parallel experiments were conducted in triplicate, including a 
three-way SILAC label swap (TEV/PBS, replicate 1: heavy/light; replicate 2: medium/heavy; replicate 3: 
light/medium). For each protein, TEV/PBS abundance ratios were compared using a one-sample t-test (XLSTAT) 
with theoretical mean log2(ratio)=0. 
Isolation of primary mouse splenocytes, fibroblasts, bone marrow cells and peripheral blood leukocytes. Mice 
(3-5 week old) were euthanized and their spleens were immediately removed before forcibly traversed through a 70 
µm cell strainer and washed with PBS. The samples were incubated with red blood cell lysis buffer and washed three 
times with PBS. The splenocytes were counted and seeded in suspension plates in complete media [RPMI with 10% 
EV-free FBS and 1:2000 dilution of cell culture grade β-mercaptoethanol] and allowed to rest for at least 4 hr and no 
more than 8 hr before experimental set up.  
Lungs from these mice were aseptically removed, washed in ice-cold PBS, minced with a scalpel blade and incubated 
in dissociation solution (8 mL of 100 mg Collagenase II and 5 mg DnaseI in HBSS) at 37°C for 30-45 min. The 
collagenase reaction was quenched by diluting with equal volume of 100% EV-Free FBS.  The dissociated tissue 
traversed a 100 µm cell strainer and the flow through was applied to a 40 µm cell strainer.  The cells were washed 
twice with PBS before plating on a 15 cm tissue culture plate in antibiotic-free media (DMEM with 10% EV-free 
FBS).  After 20-40 min, the non-adherent cells were removed; the remaining cells were washed thoroughly with PBS 
and left to rest in complete media (DMEM with 10% EV-Free FBS).  
Bone marrow was flushed from femurs and tibia of these mice with PBS using 26 gauge needles. The cells were 
traversed a 70 µm cell strainer and then treated with red blood cell lysis buffer before washed and suspended in 
complete media (RPMI with 10% EV-Free FBS and 1:2000 dilution of cell culture grade β-mercaptoethanol). The 
bone marrow cells were seeded in suspension plates for immediate experimental use. Peripheral blood was aseptically 
collected from the mouse tail vein into (green top) Na Heparin capiject tubes.  The blood samples were suspended in 
red blood cell lysis buffer and washed thoroughly with PBS prior to experimental use. 
Cell treatment in vitro.25-Hydroxycholesterol was dissolved in 100% Ethanol to make a 4 mM working stock 
solution.  Cells were washed with PBS to remove residual media and suspended in serum-free media containing 4 µM 
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of 25-Hydroxycholesterol. Reserpine and other drugs were dissolved in DMSO or water as indicated. For reserpine, a 
100 µM stock solution was used. Cultured human and mouse cells were washed with PBS and suspended in complete 
media with 10 µM of Reserpine or DMSO alone for 2 hr. 
For in vitro treatment with tumor derived extracellular vesicles, the cells were washed and counted to 1x106 cells per 
mL and suspended in appropriate media with EV-free FBS.  For each mL, 10 µg of B16F10 TEV added for mouse 
cells and 20 µg of 1205Lu TEV to human cells.  A 2 hr incubation time point was used to measure changes in IFNAR1 
cell surface level via flow cytometry.  The 4 hr incubation time point was used to analyze TEV uptake and prepare 
samples for qPCR. 
For IFN pretreatment, human cells were treated with 1000 U/mL of human IFNα or IFNβ for 12 hr and were then 
given 20 µg of labeled 1205Lu TEV for 4 hr.  Cells were then thoroughly washed with PBS and suspended in PBS 
with DAPI for flow cytometry analysis. Freshly isolated mouse splenocytes and bone marrow cells were seeded in 
suspension plates at 1x106 cells/mL and treated with 1000 U/mL with mouse IFNβ for 8 hr.  The mouse cells were 
then treated with 10 µg of B16F10 TEV for 2 hr (with gentle mixing every 30 min) to examine changes in IFNAR1 
level, or 4 hr to examine TEV uptake via flow cytometry.   
Lung Tissue Dissociation for Flow Cytometry. Lung tissues were collected from euthanized mice and washed with 
ice cold PBS.  The lung tissues are then cut into small pieces using sharp dissection scissors.  The tissue homogenate 
is then incubated in dissociation solution (3 ml/lung) (dissociation solution: 2 mg/ml Collagenase II, 1 mg/ml 
Collagenase D plus 100 μg/ml Dnase I solution) for around 1 hr with continuous agitation at 37 degree. The digested 
tissue was passed through 70 μm cell strainer and the digestion quenched with 10 ml 10% FBS RPMI medium. The 
cells were centrifuged prior to incubation with RBC lysis buffer for 5 min to remove red blood cells.  The cells are 
washed three times with PBS before prepped for flow cytometry experiments.  
EV and liposomes uptake. For in vitro assays, cells were washed and counted to 1x106 cells per mL and re-suspended 
in appropriate media with EV-free FBS.  For each mL, 10 µg of DiD-labeled B16F10 TEV for 4 hr or 1 µL of DiD-
labeled liposomes were added for 2 hr. The cells were then washed thoroughly and analyzed by flow cytometry.  
Short or long term experiments were used to analyze in vivo TEV Uptake. For short term experiments, 30 µg of DiD-
labeled TEV were injected into the tail vein of 5 to 7 week old mice. Mice that received vehicle or Reserpine were 
injected 30 min prior to TEV tail vein injection. 24 hr after injection, the spleens and bone marrow were isolated from 
the euthanized mice for immediate analysis.  For long term experiments, 8 µg of B16F10 TEV were injected into the 
tail veins of 5 to 7 week old mice three times a week for 3 weeks.  Mice that received vehicle or reserpine were injected 
30 min prior to each TEV tail vein injection.  The tissues were collected 3 days after the final injection and splenocytes 
or bone marrow cells were analyzed by flow cytometry. 
Cells that uptake EV and liposomes incorporate the DiD-dye into their plasma membranes, which allowed us to gate 
for DiD positive, DAPI negative cells using BD FACS Canto II (660/20 Red laser) or BD LSR Fortessa (670/30 Red 
laser) flow cytometers with BD FACS DIVA software.  Comparison of DiD positivity was analyzed using FlowJo 
10.4.1 (FlowJo, LLC, Ashland, OR). 
For fluorescence, lungs collected from the bone marrow transfer recipients following survival surgery were cut in 8.0 
µm sections onto glass slides. The sections were incubated in 1% paraformaldehyde in PBS for 3 min to fix tissue 
without quenching GFP and RFP signals. The tissues were washed four times with PBS before excess liquid removed 
and sections sealed with ProLong Gold Antifade Reagent with DAPI (Life Technologies) and glass coverslip.   
For immunofluorescence, OCT stored tissues were cut into 8.0 µm sections onto glass slides and fixed in 100% 
acetone at -20°C for 10 min before allowed to dry at room temperature.  The tissues were re-hydrated and washed 
with PBS.  The samples were incubated in 0.2% Triton in PBS for 10 min at room temperature and washed 3 times in 
PBS before blocking in 5% Goat Serum in PBS. Tissue samples were incubated with primary antibodies overnight at 
4°C and washed three times with PBS before incubated with respective secondary antibody at room temperature for 
1 hr. ProLong Gold Antifade Reagent with DAPI was added. Non-confocal images were taken using the Olympus 
BX51 microscope.  Confocal images were taken using Leica SP5-II FLIM. 
For Flow Cytometry Analysis, cells were washed with PBS and incubated with human or mouse Fc block diluted 
in 0.5% BSA-PBS on ice for 10 min. Cells were then incubated with APC-conjugated anti-human CD45 antibody 
and anti-human AA3 IFNAR1 antibody (Goldman et al., 1999) 30 min on ice. FITC-anti-Rabbit Alexa Fluor 
antibody was added to bind AA3 for 30 min on ice. Cells were washed to remove unbound primary and secondary 
antibodies before suspended in PBS with DAPI for flow cytometry analysis on a LSR Fortessa (BD Biosciences) 
equipped with FACS DIVA software.  
Mouse cells were washed with PBS and incubated with mouse Fc block diluted in 0.5% BSA-PBS. Afterward, cells 
were incubated with APC-conjugated anti-mouse CD45 and PE-conjugated anti-mouse IFNAR1. Cells were washed 
to remove unbound antibodies then suspended in PBS with DAPI for flow cytometry analysis on FACS Canto II and 
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LSR Fortessa (BD Biosciences) equipped with FACS DIVA. In all cases, the changes in mean fluorescence intensity 
(ΔMFI) was calculated as follows: 
ΔMFI = Sample MFI – Control (IgG) MFI 
Quantitative Real-Time PCR Analysis. Total RNA was isolated from samples using Trizol Reagent and chloroform.  
RNA concentration and purity was measured using a NanoDrop spectrophotometer.  Applied Biosystems High-
Capacity RNA-to-cDNA Kit was used to make cDNA.  The mRNA expression levels were measured by quantitative 
real-time PCR using SYBR Green Master Mix. 
For immunoprecipitation and immunoblot analysis, THP-1 cells were grown to no more than 2x106 cells per mL 
with media changed every two days.  Six hr before experiment, cells were seeded in suspension plates with fresh 
media.  Cells treated with 1000 IU/mL of human IFNα-a2 or 20 µg/mL of 1205Lu TEV for 30 min or 2 hr with 
some gentle agitation every 30 min.  The cells were transferred to pre-chilled conical tubes to remove media and 
wash cells with ice-cold PBS twice to removed media.  The cell pellets were lysed using lysis buffer with protease 
and phosphatase inhibitors as previously described.  Protein concentration detected using the Pierce BCA Protein 
Assay Kit.  For immunoprecipitation, 1mg of lysate was pre-cleared with Protein A/G beads for one hour prior to 
overnight incubation with anti-IFNAR1 (EA12) antibody (Goldman et al., 1999) with fresh Protein A/G beads.  The 
supernatant removed and the beads were washed four times with 1xTBS with 0.001% Tween-20.  The beads were 
then boiled in 4xSDS loading dye with β-mercaptoethanol for 10 min at 98°C. The whole cell lysates and 
immunoprecipitation samples were separated on SDS PAGE, transferred onto PVDF membranes and analyzed as 
previously described (Bhattacharya et al., 2013; Bhattacharya et al., 2014). 
Generating Bone Marrow Chimeric Animals. 5 week old mice were injected with 10 µg of B16F10 TEV or PBS 
into the tail vein three times a week for four weeks. The mice were euthanized and the bone marrow cells were 
flushed with PBS from the long bones. Recipient mice were irradiated with 900 rads and allowed to rest for 3 hr 
before injected with 500,000 bone marrow cells through the tail vein. The mice were given 4-6 weeks to recover 
post transplantation before being inoculated with B16F10 tumors followed by analysis of primary tumor growth and 
metastases. 
In Vivo Subcutaneous Tumor Growth. B16F10 cells at 60-70% confluence were lifted off the plate using 2mM 
EDTA in PBS. The lifted cells were washed with PBS and suspended in fresh PBS to 1x106 cells per 100 µL. The 
cells were kept on ice and 100 µL were injected subcutaneously into the flanks of mice. Tumors were measured 
every other day and resected when tumor volume reached approximately 200 mm2. 
Reserpine Adjuvant Treatment. Mice with s.c. B16F10 tumors that were approximately 30-50 mm2, began pre-
surgical treatment with reserpine (1 mg/kg dissolved in ascorbic acid and diluted in ddH2O) or vehicle (0.1% 
ascorbic acid diluted in ddH2O) three times (every other day) for one week. Once the tumor reaches approximately 
200 mm2, the tumors were resected. One week after surgery or upon healed sutures, the animals began weekly 
treatment with reserpine (or vehicle). When animals displayed signs of respiratory stress or became moribund, they 
were sacrificed and their lungs were analyzed for metastatic lesions. 
Collection of Lungs for frozen sections or H&E. Mice were euthanized and the lungs were gently perfused with 
ice cold PBS to wash out blood and prevent tissue collapse. For H&E analysis, the lungs were then perfused with 
4% paraformaldehyde solution before processed for paraffin embedding. For fluorescence and immunofluorescence 
analysis, PBS perfused lungs were then perfused with 50% OCT solution before freezing in 100% OCT for 
cryosections. 
Analysis of Tumor Number and Size in Lung Tissue. The Leica DM6000 widefield microscope was used to take 
low magnification images to generate composite images of whole, H&E stained lungs. The composite images were 
opened in ImageJ to accentuate tumor-rich areas, remove background noise, and define size of neoplasm. Composite 
images of H&E stained primary tumor were used as controls to set ImageJ parameters. ImageJ then creates a mask 
that was superimposed to the original H&E pictures to verify areas that contained cancer cells. The ImageJ mask 
was then analyzed to count number of nodules and also to calculate area of lung with tumor burden. 
 
QUANTIFICATION AND STATISTICAL ANALYSIS 
All described results are representative of at least three independent experiments (n≥5 mice per group in each 
experiment unless specified otherwise). All in vitro analyses using cells or tissues from each of these animals were 
done at least in biological triplicates (e.g. samples from 3 tumors, 3 spleens, etc). Data are presented as average ± 
S.E.M.  Statistical analysis was performed using Microsoft Excel (Microsoft) or GraphPad Prism 7 software 
(GraphPad Prism Software Inc). For analysis of proteomics data, For each protein, TEV/PBS abundance ratios were 
compared using a one-sample t-test (XLSTAT) with theoretical mean log2(ratio)=0. Unpaired Student t test was 
used for the comparison between two groups. One-way ANOVA or two-way ANOVA analysis followed by the 
Bonferroni post-hoc test were used for the multiple comparisons. Repeated-measure two-way ANOVA (mixed-
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model) followed by the Bonferroni post-hoc test was used for the analysis of tumor growth curve. The Kaplan-Meier 
curves were used to depict the survival function from lifetime data for mice and human patients; the Peto’s log-rank 
test was used to estimate the differences between the groups. The Student t-test or Fisher test were used for other 
comparisons. A value of p <0.05 was considered significant. 
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KEY RESOURCES TABLE 
REAGENT or RESOURCE SOURCE IDENTIFIER 
Antibodies 
Mouse monoclonal anti-phospho p38(T180/Y182) (28B10) Cell Signaling  Cat#9216S 
Rabbit monoclonal anti-phospho p38(T180/Y182) (28B10) Cell Signaling  Cat#4631S 
Rabbit monoclonal anti-phospho STAT1(Y701) (58D6) Cell Signaling  Cat# 9167S 
Rabbit monoclonal anti-STAT1 (9H2) Cell Signaling  Cat#9176S 
Rabbit monoclonal anti-βTRCP (D13F10) Cell Signaling  Cat#4394S 
Rabbit monoclonal anti-GAPDH (D16H11) Cell Signaling  Cat#5174S 
Rabbit monoclonal anti-β-Tubulin Cell Signaling  Cat#2146S 
Rabbit monoclonal anti- p38 (N-20) Santa Cruz Cat#SC-728 
Rat monoclonal anti-CD11b unconjugated (clone M1/70) BioLegend Cat#101202 
Mouse monoclonal anti-IFNAR1-PE (clone MAR1-5A3) BioLegend Cat#127311 
Mouse monoclonal anti-CD11b-FITC (clone M1/70) BioLegend Cat#101205 
Mouse monoclonal anti-CD45-APC (clone 30-F11) BioLegend Cat#103112 
Mouse monoclonal anti-Ubiquitin (FK2) Millipore Sigma Cat#ST1200 
Rabbit monoclonal anti-human IFNAR1 Abcam Cat#ab45172 
Rabbit polyclonal anti-Fibronectin Abcam Cat#23750 
Rabbit polyclonal anti-IFNAR1 Sinobiological Cat#50469-RP02 
mouse IgG Leinco Technologies cat# I-536 
Mouse monoclonal anti-mouse IFNAR1 (clone MAR1-5A3) Leinco Technologies cat# I-401 
Mouse monoclonal anti-human IFNAR1 (clone AA3) (Goldman et al., 1999) N/A 
Mouse monoclonal anti-human IFNAR1 (clone EA12) (Goldman et al., 1999) N/A 
Rabbit polyclonal anti-phosphoSer-IFNAR1 (Bhattacharya et al., 
2010; Bhattacharya et 
al., 2011) 
N/A 
Biological Samples   
Human extracellular vesicles This paper and (Sharma 
et al., 2018) 
N/A 
Human leukocytes This paper and (Tarhini 
et al., 2017) 
N/A 
Chemicals, Peptides, and Recombinant Proteins 
25-hydroxycholesterol Sigma-Aldrich Cat# H1015 
CAS#2140-46-7 
Reserpine Sigma-Aldrich Cat#83580 
CAS#50-55-5 
Simvastatin Sigma-Aldrich Cat#S6196 
CAS#79902-63-9 
Roglitone Sigma-Aldrich Cat#R2408 
CAS#122320-73-4 
Toremifene Sigma-Aldrich Cat#T7204 
CAS#89778-27-8 
Enclomiphene Sigma-Aldrich Cat#SML0719 
CAS#14158-65-7 
Trifluoperazine Sigma-Aldrich Cat#T8516 
CAS#79902-63-9 
Simvastatin Sigma-Aldrich Cat#S6196 
CAS#440-17-5 
Latex beads, fluorescent yellow-green Sigma-Aldrich Cat#L5155 
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LY294002 (p38 inhibitor) Selleckchem Cat# S1494 
CAS# 862507-23-1 
Recombinant mouse IFNβ PBL Assay Cat#12401-1 
Human IFNβ (1a) PBL Assay Cat# 11415-1 
human IFNα (2a) PBL Assay Cat#11100-1 
Recombinant mouse IFNγ BioLegend Cat#575306 
DiD lipophilic dye Biotium Cat# 60014 
CAS#127274-91-3 
DiD-labeled Liposomes (100 nanometers) FormuMax Liposome 
Reagents 
Cat#F60103F 
Collagenase II MP Biomedicals Cat#1005002 
CAS#9001-12-1 
Collagenase D Roche Diagnostics Cat#11088882001 
DNaseI, grade II Roche Diagnostics Cat#10104159001 
Critical Commercial Assays 
Power Sybr Green PCR Master Mix Applied Biosystems Cat#4367659 
High-Capacity cDNA Reverse Transcription Kit Applied Biosystems Cat#4368814 
Pierce BCA Protein Assay Kit ThermoFisher Cat#23225 
Experimental Models: Cell Lines 
Human: THP-1 monocytic leukemia ATCC Cat# TIB-202 
Human: 1205Lu melanoma ATCC Cat# CRL-2812 
Mouse: B16F10 melanoma ATCC Cat# CRL-6475 
Mouse: EO771 mammary adenocarcinoma CH3 Biosystems Cat#940001 
Experimental Models: Organisms/Strains 
Mouse WT C57BL/6 The Jackson Laboratory Cat#000664 
Mouse: C57BL/6 Ch25h-/- The Jackson Laboratory Cat#016263 
Mouse: C57BL/6  Ifnar1S526A (Bhattacharya et al., 
2014; Yu et al., 2015) 
N/A 
Mouse: C57BL/6  Ifnar1S526A;Ch25h-/- This paper N/A 
Mouse: C57BL/6  Mapk14f/f; Ubc9-CreERT (Katlinski et al., 2017) N/A 
Oligonucleotides 
Primers for qPCR and genotyping, see Table S3 This paper N/A 
Software and Algorithms 
FlowJo software version 10 FlowJo Software https://www.flowjo.co
m/ 
GraphPad Prism software GraphPad Software http://www.graphpad.c
om 
Microsoft Excel 2010 Microsoft Office N/A 
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Figure S1, related to Figure 1 
A. Schematic for SILAC-based Plasma Membrane Profiling screen to analyze TEV-mediated alterations in cell surface protein 
levels. These experiments were conducted in triplicate, with a three-way SILAC label swap. 
B. Characterization of TEV. Top Panel: Transmission Electron Microscopy images of TEV derived from 1205Lu, B16F10, and 
EO771 cell lines (scale bar 200nm); Bottom Panel: Nanoparticle Tracking Analysis comparing size distribution of TEV from 
different cell lines (1205Lu, B16F10, and EO771). 
C. qPCR analysis of IFNAR1 mRNA levels in THP-1 cells treated with PBS or 1205Lu TEV.  
D. Effect of TEV (10 μg/106 cells for 2 hr) or human IFNα (1000 IU/mL for 2 hr) treatment on the phosphorylation and total levels 
of indicated proteins in THP-1 cells analyzed by immunoblot. 
E. Flow analysis of IFNAR1 surface levels on THP-1 cells pretreated with vehicle or p38 inhibitor LY294002 (2 µM for 1 hr) prior 
to treatment with PBS or 1205Lu TEV (2 hr). Representative histogram (top) and MFI quantification (bottom) are shown.  
F. qPCR analysis of IFNAR1 mRNA levels in THP-1 cells treated with PBS, or extracellular vesicles derived from plasma of healthy 
donors (HDEV) or of melanoma patients (MPEV) as in Figure 1D 
G. qPCR analysis of IFNAR1 mRNA levels in peripheral blood lymphocytes from healthy donors (HD) or melanoma patients (MP) 
from two independent cohorts: MP1 (40 patients of different stages I-IV) and MP2 (20 patients in each of two groups that were 
positive (SLN+) or negative (SLN-) for sentinel lymph node metastases) 
H. IFNAR1 levels on peripheral blood leukocytes isolated from WT and SA mice after i.v. treatment with TEV from B16F10 
melanoma or EO771 mammary adenocarcinoma cells (8 μg, 3x per week for 3 weeks) or PBS. Representative histograms (left) 
and ΔMFI analyses (right) are shown.  
Quantitative data are represented as mean ± SEM; p values: * p<0.05; ** p<0.01; *** p<0.001 from Student’s t test (panels C, E, F, 
H). 
  
Table S1, related to Figure 1 
Plasma membrane proteins affected by melanoma TEV  
Protein 
IDs 
Protein 
names 
Genes TEV/CONa TEV/CONb TEV/CONc Mean Unique 
peptides 
Q9H7F0;
C9J7Z7 
Probable 
cation-
transporting 
ATPase 13A3 
ATP13A3 -1.443320449 -1.478764767 -1.67337551 -1.531820242 25 
B4DNT3
;P17181;
C9JV08;
C9J114 
Interferon 
alpha/beta 
receptor 1 
IFNAR1 -1.904224076 -1.214062619 -1.38758312 -1.501956605 6 
P20333;
B5A977 
Tumor 
necrosis 
factor 
receptor 
superfamily 
member 1B; 
Tumor 
necrosis 
factor-
binding 
protein 2 
TNFRSF1B;TNF
R1B 
-1.898134813 -1.956019469 -0.642378113 -1.498844132 2 
P41231 P2Y 
purinoceptor 
2 
P2RY2 -1.325575507 -1.279827839 -1.716112942 -1.440505429 3 
Q8NB49
;H7C0E8 
Probable 
phospholipid-
transporting 
ATPase IG 
ATP11C 0.646992084 -4.994489214 0.07553521 -1.423987307 5 
P07333;
E9PEK4 
Macrophage 
colony-
stimulating 
factor 1 
receptor 
CSF1R -1.476618706 -1.262373019 -0.656908183 -1.131966636 3 
E9PH29;
P30048 
Thioredoxin-
dependent 
peroxide 
reductase, 
mitochondrial 
PRDX3 -0.760993085 -1.497637911 -0.145873062 -0.801501353 3 
Q9NPR2
;J3KNP4
;H0YMZ
3;H0YM
R1;H0Y
LN3;H0
YNM2;H
0YMD6;
H0YKP2
;H0YN4
9 
Semaphorin-
4B 
SEMA4B -1.072816539 -0.893983426 -0.270827916 -0.74587596 4 
O95185;
E0CX15;
D6RE16;
Q8IZJ1 
Netrin 
receptor 
UNC5C 
UNC5C -0.396270408 -0.71228762 -0.722728309 -0.610428779 17 
Q96F46 Interleukin-
17 receptor A 
IL17RA -0.535206287 -0.608241513 -0.660381035 -0.601276278 8 
P11021 78 kDa 
glucose-
regulated 
protein 
HSPA5 -0.351645007 -0.023184369 0.071967056 -0.100954107 4 
Q8TDW
0 
Leucine-rich 
repeat-
containing 
protein 8C 
LRRC8C -0.344190246 0.133653784 0.049501724 -0.053678246 5 
Q8NBJ4;
F8WAT9
;C9JYM
4 
Golgi 
membrane 
protein 1 
GOLM1 -0.083217651 0.169079469 -0.146785541 -0.020307908 4 
F5GZY0
;Q06481;
F5H845;
E9PQS3;
E9PSC7 
Amyloid-like 
protein 2 
APLP2 -0.376002075 0.092186375 0.326009476 0.014064592 4 
P40939;
H0YFD6
;B4DYP
2 
Trifunctional 
enzyme 
subunit alpha, 
mitochondrial
;Long-chain 
enoyl-CoA 
hydratase;Lo
ng chain 3-
hydroxyacyl-
CoA 
dehydrogenas
e 
HADHA 0.103396924 0.200431876 0.066865524 0.123564775 4 
F5H7A2;
O00592;
F5GWY
5 
Podocalyxin PODXL 0.221815228 0.187197865 0.025588164 0.144867086 4 
P62937;
F8WE65
;C9J5S7;
Q567Q0;
Q9Y536;
F5H284 
Peptidyl-
prolyl cis-
trans 
isomerase A 
PPIA 1.00122577 -1.337882322 1.411732707 0.358358718 3 
P35408 Prostaglandin 
E2 receptor 
EP4 subtype 
PTGER4 0.53037044 0.511608391 0.564798144 0.535592325 3 
P11169;
B7Z844;
Q8TDB8
;B7ZAC
3;F5GY
R5 
Solute carrier 
family 2, 
facilitated 
glucose 
transporter 
member 
3;Solute 
carrier family 
2, facilitated 
glucose 
transporter 
member 14 
SLC2A3;SLC2A1
4 
0.221072783 0.7576231 0.657741106 0.545478996 6 
  
Figure S2, related to Figure 2 
A. Effect of pre-treatment with TEV (10 µg per 106 cells for 90 min) on activation of STAT1 by IFNβ (250 IU/mL for 30 min) or 
IFNγ (50 IU/mL for 30 min) in indicated mouse embryo fibroblasts analyzed by immunoblotting.  
B. qPCR analysis of mRNA for indicated genes in mouse splenocytes at 24 hr after they received multiple B16F10 TEV treatments 
(at t=2, 4, 6, 8, 10, 12, 14, 16, and 22 hr, 10 μg each).  
C. qPCR analysis of mRNA for indicated genes in mouse splenocytes treated with IFNβ (1000 IU/mL for 8 hr), TEV (10 µg for 4 
hr), or pre-treated with IFNβ followed by TEV as indicated. 
D. Flow cytometry analysis of WT or SA splenocytes pre-treated with PBS or mouse IFNβ (1000 IU/mL for 8 hr treated with DiD-
labeled B16F10 TEV (10 µg for 4 hr)  
E. Flow cytometry analysis of uptake of DiD-labeled TEV (10 µg for 4 hr) by splenocytes from WT, SA or Ifnar1-/- mice pre-treated 
with IgG or the IFNAR1 neutralizing antibody MAR1-5A3 (30 ng/mL for 1 hr) as indicated 
F. Flow cytometry analysis of DiD+ splenocytes and bone marrow cells isolated from mice of indicated genotypes 24 hr after i.v. 
administration of DiD-labeled B16F10 (30 μg) 
Quantitative data are represented as mean ± SEM; p values: * p<0.05; ** p<0.01; *** p<0.001 from Student’s t test (panels B, C). 
  
  
  
Figure S3, related to Figure 3 
A. Immunofluorescence analysis of CD11b+ clusters in the lungs of WT and SA animals treated with PBS or B16F10 TEV (i.v., 8 µg 
3x per week for 3 weeks) as in Figure 3C. Scale bar - 50 µm. 
B. Immunoblot analysis of fibronectin levels in the lungs of indicated mice that received PBS or B16F10 TEV for 3 weeks as 
described in Figure 3D. Levels of GAPDH serve as a loading control. 
C. Flow cytometry analysis of CD45+CD11b+ cells in the lungs of WT and SA mice administered with TEV (i.v., 8 µg 3x per week 
for 3 weeks) isolated from indicated cancer cells; quantification of flow cytometry results as % of total lung cells is shown in the 
bottom panel 
D. Flow cytometry analysis of CD45+CD11b+ cell infiltration in the lungs of SA animals treated with B16F10 TEV (i.v., 8 µg 3x per 
week for 3 weeks) and with control IgG or anti-IFNAR1 neutralizing antibody (1 mg/mouse i.p. every 5 days); quantification of 
flow cytometry results as % of total lung cells is shown in the bottom panel 
Quantitative data are represented as mean ± SEM; p values: * p<0.05; ** p<0.01; *** p<0.001 from Student’s t test (panels C, D) 
  
  
Figure S4, related to Figure 4 
A. Analysis of phagocytosis of fluorescent-labeled 0.1 µm beads by bone marrow macrophages from mice of indicated genotypes 
incubated with these beads for 0, 2 or 4 hr 
B. Primary lung fibroblasts of indicated genotypes were pre-treated with IFNβ (1000 U/mL for 8 hr) or 25HCe (4 µM for 2 hr) and 
then incubated with DiD-labeled liposomes (1 μL, 2 hr). Quantification of uptake of liposomes is shown as % of DiD+ cells.  
C. Flow cytometry analysis of uptake of DiD-labeled B16F10 TEV by splenocytes from indicated mice pre-treated with PBS, IFNβ 
(1000 U/mL for 8 hr), ethanol (EtOH), or 25HC (4 µM for 2 hr) 
D. Flow cytometry analysis of uptake of DiD-positive B16F10 TEV by splenocytes isolated from mice of indicated genotypes 24 hr 
after i.v. administration of DiD-labeled B16F10 (30 μg) 
E. qPCR analysis of relative mRNA levels of Ch25h and other genes encoding cholesterol monooxygenases (Cyp27a and Cyp46a) 
in mouse splenocytes treated in vitro with PBS, IFNβ (1000 IU/ml, 8 hr), or extracellular vesicles (10 µg for 4hr) isolated from 
primary mouse lung fibroblasts (FEV), or B16F10 melanoma cells (TEV).  
F. qPCR analysis of relative mRNA levels of Ch25h in indicated tissues isolated from naive WT and SA mice (n=4 each) 
Quantitative data are represented as mean ± SEM; p values: * p<0.05; ** p<0.01; *** p<0.001 from Student’s t test (panels A, B, 
E, F). 
  
Table S2, related to Figure 5 
Clinically relevant small molecule drugs reported to inhibit processes that involve lipid membrane fusion utilized in a mini-screen for 
suppression of TEV uptake 
 
Compound Known clinical use Inhibitor of  
Simvastatin treatment of dyslipidemia and prevention 
of cardiovascular disease 
osteoclast precursor fusion  
Rosiglitazone anti-diabetic of the thiazolidinedione class osteoclast precursor fusion  
Arbidol licensed to treat acute respiratory infections viral membrane fusion 
Toremifene and 
Enclomiphene 
selective estrogen receptor modulators viral membrane fusion  
Trifluoperazine antipsychotic of the phenothiazine class myoblast fusion 
Reserpine antihypertensive and antipsychotic agent vesicular type inhibitor of neuromediator 
reuptake 
 
 
  
 
 Figure S5, related to Figure 5 
A. Relative uptake of TEV by primary mouse splenocytes or bone marrow cells pre-treated with indicated inhibitors (10 µM for 2 hr) 
following by incubation with B16F10 DiD-labeled TEV (10 µg/106 cells, 4 hr) from melanoma cells calculated as % of uptake of 
cell pre-treated with appropriate vehicles (DMSO for simvastatin, rogliton, toremifene and reserpine and H20 for enclomiphene 
and trifluoroperazine). 
B. Flow cytometry analysis of DiD+ THP-1 cells treated as in Figure 5A. 
C. Flow cytometry analysis of DiD+ splenocytes and bone marrow cells isolated from WT mice 24 hr after i.p. injection of vehicle or 
reserpine (1 µg/kg i.p., given 30 min before TEV injection) followed by i.v. administration of DiD-labeled B16F10 (30 μg) as in 
Figure 5b 
D. qPCR analysis of indicated gene expression in bone marrow from WT mice receiving i.p. vehicle or reserpine treatment followed 
by i.v. treatment with B16F10TEV (8 μg, 3x per week for 3 weeks) 
E. Flow cytometry analysis of myeloid (CD45+CD11b+) cell infiltration in the lungs from WT mice receiving i.p. vehicle or 
reserpine and TEV treatment (as in Figure 5D). 
Quantitative data are represented as mean ± SEM; p values: * p<0.05; ** p<0.01; *** p<0.001 from Student’s t test (panels A, D, 
E). 
  
  
Figure S6, related to Figure 6 
A. Immunofluorescence analysis of lungs of WT and SA mice sacrificed 60 days after surgical removal of s.c. ~200mm2 TdTomato+ 
expressing B16F10 tumors  
B. Flow analysis (left panel) and quantification (right panel) of the TdTomato+ B16F10 cells from the lungs of mice described in 
panel A (n=3 for each group) 
C. Growth of primary B16F10 tumors inoculated s.c. at 1x106 cells in mice of indicated genotypes until the tumors reached the size 
of surgical resection (~200 mm2).  
Quantitative data are represented as mean ± SEM; p values: * p<0.05; ** p<0.01; *** p<0.001 from Student’s t test (panel B) or 
Anova test (panel C). 
 
  
 
Figure S7, related to Figure 7 
A. In vitro proliferation of B16F10 cells (untreated or treated with vehicle or reserpine at 10 µM). 
B. Transmission Electron Microscopy images of TEVs isolated from B16F10 cells cultured untreated or in the presence of vehicle or 
reserpine (10 µM for 5 days). The nanoparticle tracking analysis of TEV size distribution from these cells following is shown in 
the bottom panel. 
C. Flow cytometry analysis of CD45+CD11b+ cell infiltration of the lungs of WT animals treated with PBS or TEV (i.v., 8 µg 3x per 
week for 3 weeks) isolated from B16F10 cells treated in vitro with vehicle or reserpine (10 μM for 5 days). Quantification is 
shown in the bottom panel. 
D. Body weights of B16F10 tumor bearing WT animals treated with vehicle or reserpine (i.p. 1 mg/kg every 48 hr for 1 week)  
E. qPCR analysis of indicated gene expression in the lungs from B16F10 tumor-bearing WT mice receiving i.p. vehicle or reserpine 
treatment as in panel d.  
F. Growth of primary B16F10 tumors inoculated s.c. at 1x106 cells in WT animals treated with vehicle or reserpine (i.p. 1 mg/kg 
every 48 hr for 1 week) 
G. Growth B16F10 tumors inoculated s.c. at 1x105 cells in WT animals treated with vehicle or reserpine (i.p. 1 mg/kg, 3x per week 
for 1 week) until reaching indicated size 
Quantitative data are represented as mean ± SEM; p values: * p<0.05; ** p<0.01; *** p<0.001 from Student’s t test (panels A, 
C, E) or Anova test (panels D, F, G). 
 
  
Table S3, related to STAR methods  
List of oligonucleotides used for qPCR or mouse genotyping 
REAGENT or RESOURCE SOURCE IDENTIFIER 
Oligonucleotides for qPCR 
Primer: Human ISG15 Forward 
GAGCATCCTGGTGAGGAATAAC 
Sigma-Aldrich N/A 
Primer: Human ISG15 Reverse CGCTCACTTGCTGCTTCA Sigma-Aldrich N/A 
Primer: Human IFITM1 Forward 
TCTCAGAGGAGCCTGGCTAA 
Sigma-Aldrich N/A 
Primer: Human IFITM1 Reverse 
CCAGACTATCCTTGACCTGATGA 
Sigma-Aldrich N/A 
Primer: Human MX1 Forward 
CTTTCCAGTCCAGCTCGGCA 
Sigma-Aldrich N/A 
Primer: Human MX1 Reverse 
AGCTGCTGGCCGTACGTCTG 
Sigma-Aldrich N/A 
Primer: Human CXCL10 Forward 
AGCTCTACTGAGGTGCTATGT 
Sigma-Aldrich N/A 
Primer: Human CXCL10 Reverse 
GTACCCTTGGAAGATGGGAAAG 
Sigma-Aldrich N/A 
Primer: Human CH25H Forward 
GCTACTCTTCGACATGGAGTTC 
Sigma-Aldrich N/A 
Primer: Human CH25H Reverse 
CAGTTCCCAGACGCTCATATAC 
Sigma-Aldrich N/A 
Primer: Mouse Isg15Forward 
GGAACGAAAGGGGCCACAGCA 
Sigma-Aldrich N/A 
Primer: Mouse Isg15 Reverse 
CCTCCATGGGCCTTCCCTCGA 
Sigma-Aldrich N/A 
Primer: Mouse Ifitm1 Forward 
ATCTCCACGCCTGACCATGT 
Sigma-Aldrich N/A 
Primer: Mouse Ifitm1 Reverse 
CACCCACCATCTTCCTGTCC 
Sigma-Aldrich N/A 
Primer: Mouse Ifitm3 Forward 
CTGCTGCCTGGGCTTCATAG 
Sigma-Aldrich N/A 
Primer: Mouse Ifitm3 Reverse 
GGATGCTGAGGACCAAGGTG 
Sigma-Aldrich N/A 
Primer: Mouse Mx1 Forward 
CTCACCTCCCACATCTGTAAATC 
Sigma-Aldrich N/A 
Primer: Mouse Mx1 Reverse 
GTATGTCTGCACCGTACTTCTG 
Sigma-Aldrich N/A 
Primer: Mouse Ch25h Forward 
TGCTACAACGGTTCGGAGC 
Sigma-Aldrich N/A 
Primer: Mouse Ch25h Reverse 
AGAAGCCCACGTAAGTGATGAT 
Sigma-Aldrich N/A 
Primer: Mouse Cyp46a1 Forward 
CCTTCTTCATTGCTGGTCACG 
Sigma-Aldrich N/A 
Primer: Mouse Cyp46a1Reverse 
TCCATCACTGTGAACGCCAAG 
Sigma-Aldrich N/A 
Primer: Mouse Cyp27a1 Forward 
CCAGGCACAGGAGAGTACG 
Sigma-Aldrich N/A 
Primer: Mouse Cyp27a1 Reverse 
GGGCAAGTGCAGCACATAG 
Sigma-Aldrich N/A 
Primer: human GAPDH Forward 
AGGGCTGCTTTTAACTCTGGT 
Sigma-Aldrich N/A 
Primer: Human GAPDH Reverse 
CCCCACTTGATTTTGGAGGGA 
Sigma-Aldrich N/A 
Primer: Mouse Gapdh Forward 
AGCTTGTCATCAACGGGAAG 
Sigma-Aldrich N/A 
Primer: Mouse Gapdh Reverse 
TTTGATGTTAGTGGGGTCTCG 
Sigma-Aldrich N/A 
Oligonucleotides (PCR) for genotyping 
Primer: Mouse Ch25h Wild-type Reverse 
GTAGGCAGAAGCCCACGTAAGTGATG 
Sigma-Aldrich Recommended by 
Jackson Laboratories 
Primer #12262 
Primer: Mouse Ch25h Mutant Reverse 
GCATCAGAGCAGCCGATTGTCTGTTG 
Sigma-Aldrich Recommended by 
Jackson Laboratories 
Primer #12263 
Primer: Mouse Ch25h Common Forward 
CACAGTCTTAAGAAAAGTCGGCGGGG 
Sigma-Aldrich Recommended by 
Jackson Laboratories 
Primer #12261 
Primer: Mouse Ifnar1 Forward 
CTGGGAGCCAGGGCATAAC 
Sigma-Aldrich N/A 
Primer: Mouse Ifnar1 Reverse 
CCAGCCTTTCGGAGTGTGC 
Sigma-Aldrich N/A 
 
